Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294)

Market Cap	34.48B
Revenue (ttm)	3.91B
Net Income (ttm)	610.61M
Shares Out	1.11B
EPS (ttm)	0.55
PE Ratio	56.27
Forward PE	51.55
Dividend	0.50 (1.62%)
Ex-Dividend Date	n/a

Volume	5,210,647
Open	31.95
Previous Close	31.46
Day's Range	30.86 - 31.95
52-Week Range	23.50 - 38.10
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 25, 2025

About Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiol...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 3,517
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2023, Shenzhen Salubris Pharmaceuticals's revenue was 3.37 billion, a decrease of -3.35% compared to the previous year's 3.48 billion. Earnings were 580.07 million, a decrease of -8.95%.